BT delivered by the Alair™ System is clinically proven to be a safe and effective treatment for severe asthma, with long-lasting benefits

Asthma Intervention Research 2 (AIR2) Trial: In this trial, one of the largest sham-controlled medical device trials in pulmonary medicine, patients with severe asthma showed significant improvement compared to sham-controlled patients 1 year after treatment with BT.1

Clinically proven to reduce asthma exacerbations

Clinically proven to reduce ER visits

Supported by 5 years of clinical safety data

Supported by 5 years of clinical safety data

32%

84%

66%

79%

decrease

reduction

fewer

improvement

in asthma exacerbations (requiring systemic corticosteroids)1

in emergency room visits for respiratory-related symptoms1

asthma-related days lost from work, school, and other activities1

of patients who were treated with BT reported a significant improvement in their asthma-related quality of life1

Clinically proven to reduce asthma exacerbations

32%

decrease

in asthma exacerbations (requiring systemic corticosteroids)1

Clinically proven to reduce ER visits

84%

reduction

in emergency room visits for respiratory-related symptoms1

Supported by 5 years of clinical safety data

66%

fewer

asthma-related days lost from work, school, and other activities1

Supported by 5 years of clinical safety data

79%

improvement

of patients who were treated with BT reported a significant improvement in their asthma-related quality of life1

Clinically Effective

Asthma experts around the world talk about the effectiveness of BT

Proven to last at least 5 Years

Reduction in percentage of patients experiencing exacerbations seen at 1 year maintained for at least 5 years (primary endpoint).2

Additionally, there was a 44% decrease (average over 5 years) in the percentage of BT-treated patients having severe exacerbations, compared with 12 months prior to BT treatment.2

Reduction in ER visits seen at 1 year maintained for at least 5 years.2

Additionally, there was a 78% decrease (average over 5 years) in the percentage of BT-treated patients experiencing ER visits for respiratory symptoms, compared with 12 months prior to BT treatment.2

Proven Safety

Asthma experts around the world say BT is Safe

No increase was seen in hospitalizations, asthma symptoms, or respiratory adverse events over the course of 5 years in patients treated with Bronchial Thermoplasty delivered by the Alair System.2

No structural changes in the airways that were clinically significant were due to BT at 5 years.2

Absence of clinically significant deterioration in lung function (pre-bronchodilator FEV1) at 5 years.2

Robust clinical research for a non-drug therapy in severe asthma clearly demonstrates the long-lasting benefit of BT

Bronchial Thermoplasty is supported by 4 clinical studies in asthma patients all with 5 year follow up: 3 of the trials were randomized, controlled, clinical trials.

Understand the risks of the Bronchial Thermoplasty procedure

As with any procedure, there are risks, and individual results may vary. The most common side effect of BT is temporary worsening of respiratory-related symptoms. This side effect typically occurs within a day of the procedure and resolves within 7 days on average with standard care. There is a small (3.4% per procedure) risk of these symptoms requiring hospitalization.1

BT has been published in a variety of well-known and respected peer reviewed journals:

See more on how BT Works

The Alair Bronchial Thermoplasty System is indicated for the treatment of severe persistent asthma in patients 18 years and older whose asthma is not well controlled with inhaled corticosteroids and long-acting beta-agonists.

As with any procedure, there are risks, and individual results may vary. The most common adverse event of BT is a temporary worsening of respiratory-related symptoms. These events typically occur within one day of the BT procedure and usually resolve within a week with standard care. There is a small risk (3.4% per procedure) that symptoms may require hospitalization.2

References:

  1. Castro M, et al, for the AIR2 Trial Study Group. Am J Respir Crit Care Med. 2010;181:116-124.
  2. Wechsler M et al. J Allergy Clin Immunol. 2013 Dec;132(6):1295-302.
  3. Castro M, et al, for the AIR2 Trial Study Group. Ann Allergy Asthma Immunol. 2011;107:65-70.
  4. Pavord I, et al, and the RISA Trial Study Group. Am J Respir Care Med. 2007;176:1185-1191.
  5. Cox G, et al. N Engl J Med. 2007;356:1327-1337.
  6. Thomson N, et al, for the AIR Trial Study Group. BMC Pulm Med. 2011;1-9.
  7. Cox G, et al. Am J Respir Crit Care Med. 2006;173:965-969.

Available In: